ArticleJournal for immunotherapy of cancer2022

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.

Dionysis Papadatos-Pastos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.